



Unlocking tomorrow together™

Inception Biosciences announces consolidated shareholder support

Toronto, January 6, 2011 – Inception Biosciences Inc., operating as Inception Cord Blood Program, is pleased to announce new shareholder support effective immediately.

Management of Inception has teamed with The Succession Fund (managed by Argosy Partners) to acquire the ownership position previously held by the Company's original venture capital investors, being The New Generation Biotech (Equity) Fund and the Covington Venture Fund (each managed by Covington Capital Corporation).

Inception's medical and scientific founders and Mount Sinai Hospital continue to be strong, supportive and involved shareholders. Inception benefits from board representation from those founders, Mount Sinai Hospital, The Succession Fund and senior management. The new Inception Board is focused on growing the business.

About Inception:

Inception Cord Blood Program is Canada's largest and most established cord blood bank. With over 34,000 cord blood units banked in its state of the art facility and with 19 units released for transplant procedures or regenerative therapy trials, Inception leads the industry with regard to experience, stability, quality, governance and scientific research. Inception has developed partnerships with Mount Sinai Hospital and The Scarborough Hospital for the education of their communities about cord blood collection.

About The Succession Fund:

The Succession Fund of Toronto buys shares from selling shareholders, typically in owner-operated businesses, and always in partnership with continuing management, to resolve shareholder transition issues. When owner-operators want to buy out one or more of their shareholders, or want to sell some of their own shares for succession planning purposes, The Succession Fund buys shares in a direct secondary share purchase, and becomes the new partner for the continuing management team. The Succession Fund is a proud new investor in Inception Biosciences. Please visit www.successionfund.com or contact Larry Klar at klar@argosypartners.com or at 416-867-8090 to learn more.

Please direct inquiries to:

Richard Lockie
Chief Executive Officer



T: 905-206-2792
richardlockie@inception.com
www.inception.com